Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a limited competition grant opportunity to support the continuation of the National Clinical Trials Network (NCTN) Biospecimen Banks and the Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank). This funding aims to maintain and enhance the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens from NCI-funded clinical trials, which are crucial for advancing cancer research and treatment. The estimated total program funding is $19.1 million, with approximately six awards expected, and applications will be peer-reviewed for merit. Interested applicants can reach out to NCI DCTD CDP PIRB NOFO at NCICDPNOFO@mail.nih.gov or by phone at 240-276-7782, with the application period anticipated to open in April 2026 and close in July 2026.
Eligible Applicants
Other Eligible ApplicantsFor the NCTN Biobanks: Eligibility is limited to an institution/entity that is a recipient of an existing NCTN biobank of human biospecimens from NCI clinical trials funded under RFA-CA-20-002. For the EET Biobank: Eligibility is limited to the institution/entity that is a recipient of an existing EET biobank of human biospecimens from NCI clinical trials funded under RFA-CA-20-003.
Grant Documents
No documents available for this grant.